• 1
    Ashokkumar C, Sun Q, Gupta A, Higgs BW, Fazzolare T, Remaley L, et al. Proliferative alloresponse of T-cytotoxic cells identifies rejection-prone children with steroid-free liver transplantation. Liver Transpl 2009; 15: 978-985.
  • 2
    Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638-645.
  • 3
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5( suppl 1): S107-S114.
  • 4
    Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177.
  • 5
    Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 1998; 66: 1300-1306.
  • 6
    Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, et al. Evolution of liver transplantation. Hepatology 1982; 2: 614-636.
  • 7
    Carbone M, Neuberger J. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol 2011; 35: 446-454.
  • 8
    Sornsakrin M, Helmke K, Briem-Richter A, Ganschow R. Value of ultrasound-guided percutaneous liver biopsy in children following liver transplantation. J Pediatr Gastroenterol Nutr 2010; 51: 635-637.
  • 9
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
  • 10
    Snover DC, Freese DK, Sharp HL, Bloomer JR, Najarian JS, Ascher NL. Liver allograft rejection. An analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1987; 11: 1-10.
  • 11
    Westheim BH, Ostensen AB, Aagenæs I, Sanengen T, Almaas R. Evaluation of risk factors for bleeding after liver biopsy in children. J Pediatr Gastroenterol Nutr 2012; 55: 82-87.
  • 12
    Langnas AN, Marujo W, Stratta RJ, Wood RP, Shaw BW Jr. Vascular complications after orthotopic liver transplantation. Am J Surg 1991; 161: 76-82.
  • 13
    Mueller AR, Platz KP, Kremer B. Early postoperative complications following liver transplantation. Best Pract Res Clin Gastroenterol 2004; 18: 881-900.
  • 14
    Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Wahlstrom HE, Moore SB, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992; 16: 49-53.
  • 15
    Vaidya S, Dighe M, Kolokythas O, Dubinsky T. Liver transplantation: vascular complications. Ultrasound Q 2007; 23: 239-253.
  • 16
    Hellinger A, Roll C, Stracke A, Erhard J, Eigler FW. Impact of colour Doppler sonography on detection of thrombosis of the hepatic artery and the portal vein after liver transplantation. Langenbecks Arch Chir 1996; 381: 182-185.
  • 17
    Kok T, Slooff MJ, Thijn CJ, Peeters PM, Verwer R, Bijleveld CM, et al. Routine Doppler ultrasound for the detection of clinically unsuspected vascular complications in the early postoperative phase after orthotopic liver transplantation. Transpl Int 1998; 11: 272-276.
  • 18
    Payen DM, Fratacci MD, Dupuy P, Gatecel C, Vigouroux C, Ozier Y, et al. Portal and hepatic arterial blood flow measurements of human transplanted liver by implanted Doppler probes: interest for early complications and nutrition. Surgery 1990; 107: 417-427.
  • 19
    Ungerstedt U. Microdialysis—a new technique for monitoring local tissue events in the clinic. Acta Anaesthesiol Scand Suppl 1997; 110: 123.
    Direct Link:
  • 20
    Edsander-Nord A, Röjdmark J, Wickman M. Metabolism in pedicled and free TRAM flaps: a comparison using the microdialysis technique. Plast Reconstr Surg 2002; 109: 664-673.
  • 21
    Eide PK, Bentsen G, Stanisic M, Stubhaug A. Association between intracranial pulse pressure levels and brain energy metabolism in a patient with an aneurysmal subarachnoid haemorrhage. Acta Anaesthesiol Scand 2007; 51: 1273-1276.
  • 22
    Nowak G, Ungerstedt J, Wernerman J, Ungerstedt U, Ericzon BG. Clinical experience in continuous graft monitoring with microdialysis early after liver transplantation. Br J Surg 2002; 89: 1169-1175.
  • 23
    Waelgaard L, Thorgersen EB, Line PD, Foss A, Mollnes TE, Tønnessen TI. Microdialysis monitoring of liver grafts by metabolic parameters, cytokine production, and complement activation. Transplantation 2008; 86: 1096-1103.
  • 24
    Haugaa H, Thorgersen EB, Pharo A, Boberg KM, Foss A, Line PD, Sanengen T, Almaas R, Grindheim G, Pischke SE, Mollnes TE, Tønnessen TI. Early bedside detection of ischemia and rejection in liver transplants by microdialysis. Liver Transpl 2012; 18: 839849.
  • 25
    Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol 2010; 40: 2667-2676.
  • 26
    Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A. Liver ischemia/reperfusion injury: processes in inflammatory networks—a review. Liver Transpl 2010; 16: 1016-1032.
  • 27
    Jiang N, Zhang X, Zheng X, Chen D, Zhang Y, Siu LK, et al. Targeted gene silencing of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion injury. Am J Transplant 2011; 11: 1835-1844.
  • 28
    Rao DA, Pober JS. Endothelial injury, alarmins, and allograft rejection. Crit Rev Immunol 2008; 28: 229-248.
  • 29
    Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl 2012; 18: 166-176.
  • 30
    Wu TW, Levy GA, Yiu S, Au JX, Greig PD, Strasberg SM, et al. Delta and conjugated bilirubin as complementary markers of early rejection in liver-transplant recipients. Clin Chem 1990; 36: 9-14.
  • 31
    Goddard S, Williams A, Morland C, Qin S, Gladue R, Hubscher SG, Adams DH. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 2001; 72: 1957-1967.
  • 32
    Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78: 65-70.
  • 33
    Rygiel KA, Robertson H, Willet JD, Brain JG, Burt AD, Jones DE, Kirby JA. T cell-mediated biliary epithelial-to-mesenchymal transition in liver allograft rejection. Liver Transpl 2010; 16: 567-576.
  • 34
    Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin Sci (Lond) 2003; 104: 47-63.
  • 35
    Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158: 1703-1711.
  • 36
    Matz M, Beyer J, Wunsch D, Mashreghi MF, Seiler M, Pratschke J, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 2006; 69: 1683-1690.
  • 37
    Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558-2564.
  • 38
    Zhu J, Xu ZK, Miao Y, Liu XL, Zhang H. Changes of inducible protein-10 and regulated upon activation, normal T cell expressed and secreted protein in acute rejection of pancreas transplantation in rats. World J Gastroenterol 2006; 12: 4156-4160.
  • 39
    Zhang Z, Kaptanoglu L, Tang Y, Ivancic D, Rao SM, Luster A, et al. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 2004; 126: 809-818.
  • 40
    el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14: 562-568.
  • 41
    Bergseth G, Lambris JD, Mollnes TE, Lappegård KT. Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person. Ann Thorac Surg 2011; 91: 527-533.
  • 42
    Mikalsen B, Fosby B, Wang J, Hammarström C, Bjaerke H, Lundström M, et al. Genome-wide transcription profile of endothelial cells after cardiac transplantation in the rat. Am J Transplant 2010; 10: 1534-1544.
  • 43
    Lappegård KT, Christiansen D, Pharo A, Thorgersen EB, Hellerud BC, Lindstad J, et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci U S A 2009; 106: 15861-15866.
  • 44
    Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100: 1869-1877.
  • 45
    He S, Atkinson C, Qiao F, Cianflone K, Chen X, Tomlinson S. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest 2009; 119: 2304-2316.
  • 46
    Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6: 232-241.
  • 47
    Tilg H, Ceska M, Vogel W, Herold M, Margreiter R, Huber C. Interleukin-8 serum concentrations after liver transplantation. Transplantation 1992; 53: 800-803.
  • 48
    Kita Y, Iwaki Y, Demetris AJ, Starzl TE. Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation 1994; 57: 1037-1041.
  • 49
    Helmy A, Carpenter KL, Skepper JN, Kirkpatrick PJ, Pickard JD, Hutchinson PJ. Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. J Neurotrauma 2009; 26: 549-561.
  • 50
    Waelgaard L, Pharo A, Tønnessen TI, Mollnes TE. Microdialysis for monitoring inflammation: efficient recovery of cytokines and anaphylotoxins provided optimal catheter pore size and fluid velocity conditions. Scand J Immunol 2006; 64: 345-352.